Terry C. Yip-Fung

Data, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Reply to the letter to the editor from Gao and Liu regarding 'Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease'.

Reply to the letter to the editor from Gao and Liu regarding 'Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease'.

Journal: Gut

Published: April 16, 2026

Trends in MASLD-related cirrhosis and liver cancer across diverse populations, 2010-2023.

Trends in MASLD-related cirrhosis and liver cancer across diverse populations, 2010-2023.

Journal: Hepatology international

Published: April 15, 2026

Artificial Intelligence and Generative Models in Hepatology: From Large Language Models to Digital Pathology in Liver Disease Diagnosis and Treatment.

Artificial Intelligence and Generative Models in Hepatology: From Large Language Models to Digital Pathology in Liver Disease Diagnosis and Treatment.

Journal: Clinical and molecular hepatology

Published: February 27, 2026

Clarifying the decision rules and implementation boundaries for risk-based HCC surveillance in MASLD.

Clarifying the decision rules and implementation boundaries for risk-based HCC surveillance in MASLD.

Journal: Gut

Published: January 30, 2026

The lean phenotype in metabolic dysfunction-associated steatotic liver disease: diagnostic challenges and prognostic implications: Correspondence to editorial on "Normal-weight metabolic dysfunction-associated steatotic liver disease: reclassification, characteristics, and adverse liver outcomes across diverse populations".

The lean phenotype in metabolic dysfunction-associated steatotic liver disease: diagnostic challenges and prognostic implications: Correspondence to editorial on "Normal-weight metabolic dysfunction-associated steatotic liver disease: reclassification, characteristics, and adverse liver outcomes across diverse populations".

Journal: Clinical and molecular hepatology

Published: January 28, 2026

Challenges in defining MASLD in lean individuals: the impact of the Fatty Liver Index on phenotypic characterisation.

Challenges in defining MASLD in lean individuals: the impact of the Fatty Liver Index on phenotypic characterisation.

Journal: Gut

Published: January 20, 2026

Characteristics and Outcomes of Patients With Imaging-Defined MASLD and Histological Steatosis Grade S0.

Characteristics and Outcomes of Patients With Imaging-Defined MASLD and Histological Steatosis Grade S0.

Journal: The American journal of gastroenterology

Published: January 19, 2026

Correspondence to letter to the editor on "Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement".

Correspondence to letter to the editor on "Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement".

Journal: Clinical and molecular hepatology

Published: January 16, 2026

Correspondence to letter to the editor on "Hypothyroidism and the risk of liver-related events in patients with metabolic dysfunction-associated steatotic liver disease".

Correspondence to letter to the editor on "Hypothyroidism and the risk of liver-related events in patients with metabolic dysfunction-associated steatotic liver disease".

Journal: Clinical and molecular hepatology

Published: January 16, 2026

Machine Learning Prediction of Liver Fibrosis in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD).

Machine Learning Prediction of Liver Fibrosis in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD).

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: January 16, 2026

A cost-effectiveness evaluation framework for treatment for metabolic dysfunction-associated steatohepatitis: Potential and concerns: Editorial on "Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease".

A cost-effectiveness evaluation framework for treatment for metabolic dysfunction-associated steatohepatitis: Potential and concerns: Editorial on "Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease".

Journal: Clinical and molecular hepatology

Published: December 28, 2025

Long-term incidence of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.

Long-term incidence of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.

Journal: Gastroenterology

Published: December 11, 2025

Showing 1-12 of 31

Last Updated: 09/26/2026